Volume 82 | ESPE2014 | Next issue

ESPE 2014

Dublin, Ireland
18 Sep 2014 - 20 Sep 2014

Card image cap
Dublin, Ireland; 18-20 September 2014. Further information

Poster Presentations

Fat Metabolism & Obesity (2)

Impairment of Adipose Tissue in Prader-Willi Syndrome Rescued by GH Treatment
aINSERM, UMR 1048, Institut des Maladies Métaboliques et Cardiovasculaires I2MC, Toulouse, France; bUniversité Paul Sabatier, UMR 1048, Toulouse, France; cUnité d’Endocrinologie, Obésité, Maladies Osseuses, Génétique et Gynécologie Médicale. Centre de Référence du Syndrome de Prader–Willi, Hôpital des Enfants, Toulouse, France; dAxe Pédiatrique du CIC 9302/INSERM, Hôpital des Enfants, Toulouse, France; eINSERM, UMR 1043, Toulouse, France
hrp0082p1-d3-125
Dysautonomia and Acyl Ghrelin in Prader-Willi syndrome
aThe University of Queensland, Brisbane, Queensland, Australia; bMater Children’s Hospital, Brisbane, Queensland, Australia, cRoyal North Shore Hospital, Sydney, New South Wales, Australia, dQueensland University of Technology, Brisbane, Queensland, Australia, eMater Research Institute, The University of Queensland, Brisbane, Queensland, Australia
hrp0082p1-d3-126
Infancy Lipidomic Analyses and Associations with Early Nutrition and Growth
aUniversity of Cambridge, Cambridge, UK; bMRC Human Nutrition Centre, Cambridge, UK
hrp0082p1-d3-127
Acylated and Unacylated Ghrelin Levels in Children and Young Adults with Prader-Willi Syndrome
aDutch Growth Research Foundation, Rotterdam, The Netherlands; bDepartment of Pediatric Endocrinology, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands; cPrader–Willi Reference Center, INSERM U563, Children’s Hospital Toulouse, Toulouse, France; dDivision of Pediatric Endocrinology, University of Lyon, Hôpital Femme-Mère-Enfant, Bron/Lyon, France; eErasmus Medical Center, Department of Internal Medicine, Rotterdam, The Netherlands; fAlizé Pharma, Ecully, France
hrp0082p1-d3-128
The Effect of Honey on Plasma Glucose and Insulin Concentrations in Obese Prepubertal Girls
aDivision of Endocrinology, Metabolism and Diabetes, First Department of Pediatrics, University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Attiki, Greece; bDepartment of Biological Chemistry, University of Athens Medical School, Athens, Attiki, Greece; cDepartment of Clinical Biochemistry, University of Athens Medical School, ‘Aghia Sophia’ Children’s Hospital, Athens, Attiki, Greece
hrp0082p1-d3-129
Features of Neuroendocrine Status in Children with Different Forms of Obesity
aBelarusian State Medical University, Minsk, Belarus; b10th State Clinic, Minsk, Belarus; cNational Academy of Sciences of Belarus, Minsk, Belarus
hrp0082p1-d3-130
Under-Diagnosed Beckwith-Wiedemann Syndrome Among Early-Onset Obese Children
aHospital Infantil Universitario Niño Jesús; Endocrinology Department IIS La Princesa, Univerisidad Autónoma de Madrid; Pediatrics Department, Madrid, Spain; bInstituto de Salud Carlos III, CIBER Fisiopatología de la Obesidad y Nutrición, Madrid, Spain; cUniversitat Pompeu Fabra, Genetics Unit, Hospital del Mar Research Institute (IMIM), Program in Neurosciences, Barcelona, Spain; dInstituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Barcelona, Spain
hrp0082p1-d3-131
Impact of Maternal and Fetal Inflammatory Markers on Neonatal and Infant Adiposity
aUniversity College Dublin, Dublin, Ireland; bNational Maternity Hospital, Dublin, Ireland; cRoyal College of Surgeons of Ireland, Dublin, Ireland; dOur Lady’s Childrens Hospital Crumlin, Dublin, Ireland
hrp0082p1-d3-132
Can We Predict the Risk of Obesity?
aPediatric Endocrinology Unit, Miguel Servet Hospital, Zaragoza, Spain; bGodday Solutions SL, Zaragoza, Spain; cAndrea Prader Foundation, Zaragoza, Spain
hrp0082p1-d3-133
Can Hypothalamic Obesity be Treated with Stimulants?
Division of Pediatric Endocrinology und Diabetes, University Hospital for Pediatric and Adolescent Medicine, Ulm, Germany
hrp0082p1-d3-134